Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · InfuSystem Holdings, Inc (INFU)

InfuSystem Q3 revenue rises 3.0% to $37.6 million; full-year guidance reaffirmed

Positive Impact 3 of 5 earnings Written later

InfuSystem reported third-quarter 2026 net revenue of $37.6 million, up 3.0% from the prior year, and net income of $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11, a year earlier. The company reaffirmed its full-year 2026 guidance, which reflects a previously announced GE Healthcare contract restructuring that lowered reported revenue.

Key points

  • Net revenue $37.6 million, up 3.0% from $36.5 million; Patient Services up 15%, Device Solutions down 17%
  • Net income $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11, in Q3 2025
  • Adjusted EBITDA (non-GAAP) $9.4 million, up 12.5%, with a margin of 24.9%
  • Full-year 2026 guidance reaffirmed: pro-forma revenue growth of 6% to 8% and Adjusted EBITDA margin in the low-to-mid 20% range; conference call November 10, 2026 at 9:00 a.m. Eastern Time

The filing

CompanyInfuSystem Holdings, Inc (INFU)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:31 AM ET
Accession number0001628280-26-070512

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.